GlaxoSmithKline PLC Director/PDMR Shareholding (0273L)

TIDMGSK

RNS Number : 0273L

GlaxoSmithKline PLC

07 September 2021

   GlaxoSmithKline plc   (the ' Company ') 

Transaction notification

 
 1.    Details of PDMR/person closely associated with them ('PCA') 
====  ========================================================================================= 
 a)    Name                                   Mr L Miels 
====  ======================================  ================================================= 
 b)    Position/status                        Chief Commercial Officer 
====  ======================================  ================================================= 
 c)    Initial notification/                  Initial notification 
        amendment 
====  ======================================  ================================================= 
 2.    Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
====  ========================================================================================= 
 a)    Name                                   GlaxoSmithKline plc 
====  ======================================  ================================================= 
 b)    LEI                                    5493000HZTVUYLO1D793 
====  ======================================  ================================================= 
 3.    Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transaction(s) 
        has been conducted 
====  ========================================================================================= 
 a)    Description of                         Ordinary shares of 25 pence each ('Ordinary 
        the financial                          Shares') 
        instrument                             ISIN: GB0009252882 
====  ======================================  ================================================= 
 b)    Nature of the                          Following the vesting on 4 September 2021 
        transaction                            of 25% of an award made on 14 February 
                                               2018 under the GlaxoSmithKline Deferred 
                                               Investment Award Programme, Mr Miels will 
                                               receive a cash payment of GBP409,730.64 
                                               less applicable tax withholding in respect 
                                               of 27,706.968 notional Ordinary Shares. 
====  ======================================  ================================================= 
 c)    Price(s) and                            Price(s)               Volume(s) 
        volume(s) 
====  ======================================   =====================  ======================= 
   GBP14.788                                                          27,706.968 
   =================================================================  ======================= 
 
 d)    Aggregated information                 N/A (single transaction) 
==== 
  Aggregated volume 
   Price 
 ==============================================================  ============================== 
 e)    Date of the transaction                2021-09-04 
====  ======================================  ================================================= 
 f)    Place of the                           N/A 
        transaction 
====  ======================================  ================================================= 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHEDLFBFKLEBBB

(END) Dow Jones Newswires

September 07, 2021 11:54 ET (15:54 GMT)